Hong Kong stock market anomaly | CRO concept stocks continue to rebound, with the Pharmaron Group leading the way. Investors may gradually become desensitized to external shocks.
CRO concept stocks continued to rebound, with WUXI BIO leading the way. WUXI BIO rose by 4.82%, GENSCRIPT BIO by 5.37%, WUXI APPTEC by 4.45%, and TIGERMED by 2.39%. WUXI APPTEC clarified the US national security risks, and investors are gradually becoming desensitized to US-related news. Xiangcai Securities predicts that the growth in pharmaceutical R&D spending and the increase in outsourcing penetration will support the development of the CRO industry. The cost-effectiveness of the global biotech industry is evident, and the innovative drug investment and financing environment is expected to improve, showing optimism for the long-term prospects of the CRO industry.
Zhitong App learned that the concept stocks related to CRO continued to rebound. As of the time of publication, WUXI BIO (02269) rose by 4.82% to HKD 19.12, GENSCRIPT BIO (01548) rose by 5.37% to HKD 15.7, WUXI APPTEC (02359) rose by 4.45% to HKD 50.45, and TIGERMED (03347) rose by 2.39% to HKD 27.8.
On the news front, in the afternoon of February 18th, WUXI APPTEC once again issued a clarification announcement, reiterating that it "has not, does not, and will not pose a national security risk to the United States." Industry insiders believe that although American politicians continue to hype up the follow-up actions of the Pharmaron Group, investors may gradually become desensitized to news related to the United States.
Xiangcai Securities pointed out that it is expected that both domestic and foreign R&D expenditures in the pharmaceutical industry will continue to grow, and the penetration rate of pharmaceutical R&D outsourcing will continue to increase, serving as an important support for the development of the CXO industry. Although the current performance of CXO is under pressure due to the decline in domestic and foreign pharmaceutical investment and financing, given the gradual weakening of the expected rate hikes by the Federal Reserve and the clearing of the global biotech valuation bubble over the past two years, the cost-effectiveness of the global biotech industry has become apparent. The environment for innovative drug investment and financing is expected to gradually improve, and there is optimism for the long-term improvement of CXO in the short term.